With this acquisition, Lupin will gain access to Medisol s portfolio of seven injectable products across four therapeutic areas, including pain management, anti-inflammatory, cardiovascular diseases,.
Lupin Ltd today announced that it has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French Ministry of Economy and Finance.
Founded in 2011, Medisol specialises in generics injectable products and is engaged in developing and commercialising its products in France, in pharmacies and in hospitals.